Pre-made Atibuclimab benchmark antibody ( Whole mAb, anti-CD14 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-035

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-035 Category Tag

Product Details

Pre-Made Atibuclimab biosimilar, Whole Mab: Anti-CD14 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Atibuclimab (formerly IC 14) is a recombinant chimeric monoclonal antibody being developed by Implicit Bioscience for the treatment of acute lung injury, motor.

Products Name (INN Index)

Pre-Made Atibuclimab biosimilar, Whole Mab: Anti-CD14 therapeutic antibody

INN Name

Atibuclimab

Target

CD14

Format

Whole mAb

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG4

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2020

Companies

ICOS Corporation,Implicit Bioscience

Conditions Approved

NA

Conditions Active

Acute lung injury,COVID-19

Conditions Discontinued

Adult respiratory distress syndrome,Motor neuron disease,Septic shock

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

CD14

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide